ACADIA Pharmaceuticals Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing, not a Q4-only report; quarterly figures are noted where relevant. Unless stated otherwise, financial amounts are in U.S. dollars.
Business context
ACADIA is a development-stage biopharmaceutical company focused on small-molecule therapies for neurological and central nervous system disorders. It had no product-sale revenue and depended primarily on collaboration and grant income. Its lead candidate, pimavanserin, was in Phase III development for Parkinson’s disease psychosis (PDP); ACADIA held worldwide commercialization rights. Other programs included Allergan-partnered chronic pain and glaucoma candidates and two preclinical neurological programs.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 | Change / context |
|---|---|---|---|
| Collaborative revenue | $4.9 million | $2.1 million | Up $2.8 million, mainly from recognizing $3.2 million of deferred Meiji revenue after that collaboration ended. |
| Research and development | $18.8 million | $17.3 million | Up $1.5 million, primarily higher pimavanserin clinical costs. |
| General and administrative | $7.0 million | $7.6 million | Down $0.6 million; 2011 included a Swedish lease termination charge. |
| Operating loss | $20.9 million | $22.9 million | Operating margin approximately -426% in 2012, reflecting low collaboration revenue relative to expenses. |
| Net loss | $20.8 million | $22.8 million | Loss per share: $0.38 in 2012 versus $0.44 in 2011. |
| Operating cash flow | $(21.6) million | $(19.9) million | Cash used increased by $1.7 million. |
| Cash, equivalents and investments | $108.0 million | $31.0 million | Increase primarily funded by 2012 equity offerings. |
| Working capital | $102.6 million | $25.8 million | Current assets were $108.5 million and current liabilities $5.9 million. |
| Debt | No debt reported | $32,000 current debt | 2012 balance-sheet debt was zero. |
Financing provided $98.2 million net cash in 2012, including $80.5 million from a December private placement and $17.1 million net from the at-the-market (ATM) program. The company reported $84.98 million in stockholders’ equity and a $367.7 million accumulated deficit at year-end. Fourth-quarter 2012 revenue was $380,000 and net loss was $6.81 million.
Material changes versus the prior period
- Revenue rose from 2011, but remained collaboration-based and included a one-time $3.2 million recognition tied to termination of the Meiji Seika Pharma collaboration in July 2012. Allergan revenue was approximately $1.1 million in both years.
- R&D spending increased as external clinical costs for pimavanserin rose; management expected further increases as trials advanced.
- Cash and investments increased substantially following equity financings. Share issuance also increased dilution: 73.3 million common shares were issued and outstanding at year-end, in addition to 5.35 million shares classified as redeemable.
- For context, 2010 revenue was $42.1 million, including $39.5 million recognized from the concluded Biovail collaboration; that result was not representative of recurring revenue.
Outlook, risks and unusual items
- Clinical outlook: The pivotal Phase III -020 PDP trial met its primary efficacy endpoint (p=0.001) and key motor-tolerability endpoint. ACADIA planned a confirmatory Phase III -021 trial for the first half of 2013 and a Phase II Alzheimer’s disease psychosis trial for the second half of 2013. Pimavanserin remained investigational, with no approved products or product revenue.
- Funding outlook: Management estimated 2013 operating cash use of $26–$30 million and said existing resources plus anticipated collaboration payments should fund operations into 2015. This was an estimate, not a guarantee; the company expected to need significant future financing and warned that unavailable capital could force program delays or reductions.
- Development and partner risks: A prior Phase III PDP study had failed, and the confirmatory trial’s outcome was uncertain. Allergan had said it was seeking a partner for the chronic pain program; failure to find one could slow or halt development. Meiji’s program was discontinued.
- ATM registration and rescission exposure: ACADIA disclosed that a delayed Form 8-K filing made it ineligible to use its Form S-3 shelf registration for certain 2012 ATM sales. The shares could be treated as unregistered, exposing the company to potential rescission claims of up to approximately $17.7 million plus statutory interest, as well as possible regulatory penalties. No claims had been asserted as of the filing; potential rights were expected to expire in 2013.
- Other commitments: Contract research and service agreements represented up to approximately $15.1 million of future services, generally stoppable on short notice. Potential Ipsen milestone payments were up to $10.5 million if specified events occurred. Operating lease commitments totaled $281,000, all due within one year.
- Other disclosures: The company reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions. No legal proceedings were reported. The board adopted a change-in-control severance plan in March 2013.
Important facts for investors to verify
- Confirm the complete -020 results and subsequent -021 trial progress, design, safety findings and regulatory requirements.
- Track cash burn against the $26–$30 million 2013 estimate and the stated runway into 2015, including timing and certainty of collaboration receipts.
- Assess the status and financial resolution of potential ATM rescission claims, statutory interest and any regulatory action.
- Review dilution from the private placement, ATM shares, warrants, options and redeemable-stock classification; reconcile share counts by date.
- Check whether Allergan secured a partner for chronic pain development and whether collaboration research terms or funding were extended beyond March 2013.
- Evaluate whether future capital needs, clinical costs or milestone obligations differ materially from management’s estimates; the filing provides no product-sales guidance because no product was approved.